Infliximab Intravenous (Iv) Solution 100 mg/20 mL, 100 mg/10 mL Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) Solution

Available Strengths: 100 mg/20 mL, 100 mg/10 mL

Reference Brands: Remicade (US & EU)

Category: Arthritis

Infliximab is a monoclonal antibody that binds to TNF-alpha, blocking its role in inflammation. It reduces joint swelling, pain, and tissue damage in rheumatoid arthritis. Benefits include rapid symptom relief, slowed disease progression, improved joint function, and effective management of severe autoimmune conditions when administered intravenously.

Product Description:

Infliximab IV solution is approved in the EU and US for treating rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Remicade are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for infliximab IV formulations, ensuring adherence to European and American standards for safe, effective biologic therapy, helping you navigate complex regulatory frameworks seamlessly.